题名

使用Clozapine之精神病患者的血液監測

DOI

10.29478/TJP.200406.0006

作者

黃輝慶；劉偉民；張豫立；孔繁錦；楊孟達；張堯舜

关键词

clozapine ； 白血球減少 ； 嗜中性球減少 ； 嗜伊紅球過多

期刊名称

台灣精神醫學

卷期/出版年月

18卷2期（2004 / 06 / 01）

页次

128 - 134

内容语文

繁體中文
中文摘要

目的：本研究之目的在於評估clozapine治療中所導致之血液學副作用，並與其服藥前之基礎值進行分析比較。方法：本研究收集使用clozapine之病人，利用Student t及chi-square test評估並分析各類血液學副作用與病患特性及給藥前血液學基礎值之關聯性。結果：clozapine平均服用天數288.8天；平均每日劑量159.7mg/day。導致白血球減少、嗜中性白血球減少、嗜伊紅血球過多、及血小板低下之案例數分別為12（8%）、26（17%）、29（19%）、5（3%）；同時發生嗜中性白血球減少症及嗜伊紅血球過多者有5例（3%）。服藥前白血球計數少於6000/mm3者較易發生異常（30.6%）；反之計數大於6000/mm3者較少發生異常（13.8%）（P=0.01）。結論：本研究中病患服用clozapine之平均日劑量明顯低於clozapine在英美等國使用的平均劑量；但平均起始劑量則高於藥典建議的25mg/day。血液學副作用之發生型式與文獻所載吻合，皆為暫時性而無臨床危害。發生白血球減少或嗜中性白血球減少症的病人，其服藥前白血球計數及嗜中性白血球計數平均值明顯低於未發生者的平均值。
主题分类 醫藥衛生 > 社會醫學
参考文献
  1. (2002).Drugs Facts and Comparisons.St. Louis:A Wolters Kluwer Co..
  2. Adityanjee MD,Jampala VC,Mohan MS(1997).Eosinophilia, agranulocytosis and clozapine.Br J Psychiatry,171,485-486.
  3. Alphs LD,Anand R(1999).Clozapine: the commitment to patient safety.J Clin Psychiatry,60,39-42.
  4. Alvir JM,Lieberman JA,Safferman AZ,Schwimmer JL,Schaaf JA(1993).Clozapine-Induced agranulocytosis-Incidence and risk factors in the United States.N Engl J Med,329,162-167.
  5. Ames D,Wirshing WC,Baker RW(1996).Predictive value of eosinophilia for neutropenia during clozapine treatment.J Clin Psychiatry,57,579-581.
  6. Anand P,Ronald P(1995).Clozapine and Leukocytosis.J Clin Psychopharmacol,15,286-287.
  7. Atkin K,Kendall F,Gould D,Freeman H,Liberman J,O`Sullivan D(1996).Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.Br J Psychiatry,169,483-488.
  8. Bailey P(1997).Clozapine treatment, eosinophilia and agranulocytosis.Br J Psychiatry,171,90.
  9. Busto U,Naranjo CA,Sellers EM(1982).Comparison of two recently published algorithms for assessing the probability of adverse drug reactions.Br J Clin Pharmacol,13,223-227.
  10. Centorrino F,Baldessarini RJ,Flood JG,Kando JC,Frankenburg FR(1995).Relation of leukocyte counts during clozapine treatment to serum concentrations of clozapine and metabolites.Am J Psychiatry,152,610-612.
  11. Chakos M,Liberman J,Hoffman E,Bradford D,Sheitman B(2001).Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.Am J Psychiatry,158,518-526.
  12. Chang WH,Lin SK,Lang HY(1997).Clozapine dosage and plasma drug concentrations.J Formos Med Assoc,96,599-605.
  13. Clozapine.Micromedex.1974-2003 Thomson MICROMEDEX.
  14. Dev VJ,Rosenberg T,Krupp P(1994).Agranulocytosis and clozapine.BMJ,309,54.
  15. Durst R,Dorevitch A,Frankel Y(1993).Platelet dysfunction associated with clozapine therapy.South Med J,86,1170-1172.
  16. Fischbach FT(2000).A Manual of Laboratory & Diagnostic Tests.NY:Lippincott-Raven.
  17. Fisher N,Baigent B(1996).Treatment with clozapine: black patient`s low white cell counts currently mean that they cannot be treated.BMJ,313,1262.
  18. Fleischhacker WW,Hummer M,Kurz M(1994).Clozapine dose in the United State and Europe: implications for therapeutic and adverse effects.J Clin Psychiatry,55,78-81.
  19. Galletly C,Wilson D,McEwen S(1996).Eosinophilia associated with decreasing neutrophil count in a clozapine-treated patient.J Clin Psychiatry,57,40-41.
  20. Hampson ME(2000).Clozapine-induced thrombocytosis.Br J Psychiatry,176,400.
  21. Hong X,Wang X(2001).Agranulocytosis and neutropenia with typical and atypical neuroleptics.Am J Psychiatry,158,1736-1737.
  22. Hummer M,Kurt M,Barnas C,Saria A,Fleischhacker WW(1994).Clozapine-induced transient white blood count disorders.J Clin Psychiatry,55,429-432.
  23. Hutchinson TA,Leventhal JM,Kramer MS,Karch FE,Lipman AG,Feinstein AR(1979).An algorithm for the operational assessment of adverse drug reactions.JAMA,242,633-638.
  24. Leonid S(1995).White-blood-cell monitoring and clozapine.Lancet,346,849.
  25. Lin CH,Younger WY Yu,Hsu CP(1999).Adverse effects of clozapine in the treatment of schizophrenia.Taiwanese J Psychiatry,13,209-218.
  26. Liu HC,Wei FC,Lin SK(1995).Plasma clozapine concentration and treatment response in refractory schizophrenic patients.Chin Psychiatry,9,273-282.
  27. Lucht MJ,Rietschel M(1998).Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms.J Clin Psychiatry,59,195-197.
  28. Munro J,O`sullivan D,Andrews C,Arana A,Mortimer A,Kerwin R(1999).Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance.Br J Psychiatry,175,576-580.
  29. Naranjo CA,Busto U,Sellers EM(1981).A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther,30,239-245.
  30. Pichel U(2000).Incidence of leukopenia and agranulocytosis from clozapine.J Psychiatr Assoc Thailand,45,230-235.
  31. Tharyan P(1998).Haematological monitoring with clozapine therapy in India.Br J Psychiatry,172,540.
  32. Wahlbeck K,Cheine M,Essali A,Adams C(1999).Evidence of clozapine`s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.Am J Psychiatry,156,990-999.
  33. Wesson ML,Finnegan DM,Clark PI(1996).Continuing clozapine despite neutropenia.Br J Psychiatry,168,217-220.
  34. Young NS(1994).Agranulocytosis.JAMA,271,935-938.
  35. Zhang M,Owen RR,Pope SK(1996).Cost-effectiveness of clozapine monitoring after the first 6 months.Arch Gen Psychiatry,53,954-958.
print cancel